Abbott Laboratories (ABT) EBIT (2009 - 2026)

Abbott Laboratories' EBIT history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, EBIT fell 20.56% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $7.7 billion (up 8.03% YoY), while the FY2025 annual figure was $8.1 billion, up 17.99% from the prior year.
• EBIT came in at $1.3 billion for Q1 2026 at Abbott Laboratories, down from $2.3 billion in the prior quarter.
• In the past five years, EBIT ranged from a high of $2.9 billion in Q1 2022 to a low of $1.3 billion in Q4 2022.
• A 5-year average of $1.8 billion and a median of $1.8 billion in 2022 frame the typical range for EBIT.
• Across the five-year window, EBIT soared 70.69% in 2022 and tumbled 48.18% in 2023, its largest moves.
• Abbott Laboratories' EBIT stood at $1.3 billion in 2022, then surged by 36.5% to $1.8 billion in 2023, then advanced by 7.36% to $1.9 billion in 2024, then grew by 17.79% to $2.3 billion in 2025, then tumbled by 40.25% to $1.3 billion in 2026.
• According to Business Quant data, EBIT over the past three periods registered $1.3 billion, $2.3 billion, and $2.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison